Top Key Companies for Tumor NGS Detection Market: Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq, AmoyDx, Burning Rock Medicine, Perkin Elmer, Qiagen NV, Partek, Illumina Inc., Pacific Biosciences of California Inc., Life Technologies Corporation, GTH.O, Paradigm Diagnostics, Oxford Nanopore Technologies Ltd., Eurofins Scientific S.E..
Global Tumor NGS Detection Market Size was estimated at USD 25.39 million in 2022 and is projected to reach USD 35.33 million by 2028, exhibiting a CAGR of 5.66% during the forecast period.
Global Tumor NGS Detection Market Overview And Scope:
The Global Tumor NGS Detection Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Tumor NGS Detection utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Tumor NGS Detection Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor NGS Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tumor NGS Detection market.
Global Tumor NGS Detection Market Segmentation
By Type, Tumor NGS Detection market has been segmented into:
Medical Equipment
Consumables
By Application, Tumor NGS Detection market has been segmented into:
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Other
Regional Analysis of Tumor NGS Detection Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Tumor NGS Detection Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Tumor NGS Detection market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Tumor NGS Detection market.
Top Key Companies Covered in Tumor NGS Detection market are:
Agilent
Thermo Fisher Scientific
BGI Group
Roche Foundation Medicine
Sinopharm Group
Fosunpharma
Novogene
Geneseeq
AmoyDx
Burning Rock Medicine
Perkin Elmer
Qiagen NV
Partek
Illumina Inc.
Pacific Biosciences of California Inc.
Life Technologies Corporation
GTH.O
Paradigm Diagnostics
Oxford Nanopore Technologies Ltd.
Eurofins Scientific S.E.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Tumor NGS Detection Market by Type
5.1 Tumor NGS Detection Market Overview Snapshot and Growth Engine
5.2 Tumor NGS Detection Market Overview
5.3 Medical Equipment
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Medical Equipment: Geographic Segmentation
5.4 Consumables
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Consumables: Geographic Segmentation
Chapter 6: Tumor NGS Detection Market by Application
6.1 Tumor NGS Detection Market Overview Snapshot and Growth Engine
6.2 Tumor NGS Detection Market Overview
6.3 Companion Diagnostics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Companion Diagnostics: Geographic Segmentation
6.4 Early Cancer Screening
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Early Cancer Screening: Geographic Segmentation
6.5 Drug Discovery
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Drug Discovery: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2026-2035F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Tumor NGS Detection Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Tumor NGS Detection Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Tumor NGS Detection Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 AGILENT
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 THERMO FISHER SCIENTIFIC
7.4 BGI GROUP
7.5 ROCHE FOUNDATION MEDICINE
7.6 SINOPHARM GROUP
7.7 FOSUNPHARMA
7.8 NOVOGENE
7.9 GENESEEQ
7.10 AMOYDX
7.11 BURNING ROCK MEDICINE
7.12 PERKIN ELMER
7.13 QIAGEN NV
7.14 PARTEK
7.15 ILLUMINA INC.
7.16 PACIFIC BIOSCIENCES OF CALIFORNIA INC.
7.17 LIFE TECHNOLOGIES CORPORATION
7.18 GTH.O
7.19 PARADIGM DIAGNOSTICS
7.20 OXFORD NANOPORE TECHNOLOGIES LTD.
7.21 EUROFINS SCIENTIFIC S.E.
Chapter 8: Global Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Medical Equipment
8.2.2 Consumables
8.3 Historic and Forecasted Market Size By Application
8.3.1 Companion Diagnostics
8.3.2 Early Cancer Screening
8.3.3 Drug Discovery
8.3.4 Other
Chapter 9: North America Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Medical Equipment
9.4.2 Consumables
9.5 Historic and Forecasted Market Size By Application
9.5.1 Companion Diagnostics
9.5.2 Early Cancer Screening
9.5.3 Drug Discovery
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Medical Equipment
10.4.2 Consumables
10.5 Historic and Forecasted Market Size By Application
10.5.1 Companion Diagnostics
10.5.2 Early Cancer Screening
10.5.3 Drug Discovery
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Medical Equipment
11.4.2 Consumables
11.5 Historic and Forecasted Market Size By Application
11.5.1 Companion Diagnostics
11.5.2 Early Cancer Screening
11.5.3 Drug Discovery
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Medical Equipment
12.4.2 Consumables
12.5 Historic and Forecasted Market Size By Application
12.5.1 Companion Diagnostics
12.5.2 Early Cancer Screening
12.5.3 Drug Discovery
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Medical Equipment
13.4.2 Consumables
13.5 Historic and Forecasted Market Size By Application
13.5.1 Companion Diagnostics
13.5.2 Early Cancer Screening
13.5.3 Drug Discovery
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Tumor NGS Detection Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Medical Equipment
14.4.2 Consumables
14.5 Historic and Forecasted Market Size By Application
14.5.1 Companion Diagnostics
14.5.2 Early Cancer Screening
14.5.3 Drug Discovery
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Tumor NGS Detection Scope:
|
Report Data
|
Tumor NGS Detection Market
|
|
Tumor NGS Detection Market Size in 2025
|
USD XX million
|
|
Tumor NGS Detection CAGR 2025 - 2032
|
XX%
|
|
Tumor NGS Detection Base Year
|
2024
|
|
Tumor NGS Detection Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq, AmoyDx, Burning Rock Medicine, Perkin Elmer, Qiagen NV, Partek, Illumina Inc., Pacific Biosciences of California Inc., Life Technologies Corporation, GTH.O, Paradigm Diagnostics, Oxford Nanopore Technologies Ltd., Eurofins Scientific S.E..
|
|
Key Segments
|
By Type
Medical Equipment
Consumables
By Applications
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Other
|
